{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-003940","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.987264+00:00","generated_at":"2026-05-16T03:04:35.810634+00:00","sec_items":["1.01","3.02","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Catheter Precision secures up to $36.5M institutional financing; converts $9M liabilities into equity","bullets":["CEO David Jenkins exchanged royalty rights for ~9,490 shares of Series J Preferred Stock convertible into 6,083,005 common shares at $1.56, subject to stockholder approval.","ATM equity offering program terminated; no future equity lines or forward-priced agreements anticipated.","Short-term notes converted to long-term debt with maturities of 2-3 years.","Additional $9M in short and long-term liabilities converted into equity, strengthening balance sheet.","Up to $36.5M in institutional financing secured to expand market presence and advance growth initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-003940","json":"https://secwatch.observer/filing/0001437749-26-003940.json","markdown":"https://secwatch.observer/filing/0001437749-26-003940.md","text":"https://secwatch.observer/filing/0001437749-26-003940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003940/0001437749-26-003940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003940/vtak20260211_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:04:35.810634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8ed63db6d40c2ca204e6347b4a9502104fa0180","claim":"Catheter Precision, Inc. issued 9,489.488 shares of Series J Preferred Stock of preferred stock to David A. Jenkins and FatBoy Capital, LP for accrued royalty amounts totaling a net present value equal to $9,489,487.81.","evidence_excerpt":"Settlement Agreements dated January 9, 2023 between the Company and the Holders previously disclosed by the Company accrued royalty amounts totaling a net present value equal to $9,489,487.81 as of December 31, 2025 are being exchanged for 9,489.488 shares of Series J Preferred Stock, collectively. Per the Exchange Agreements, the accrued royalty amounts and the","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003940/0001437749-26-003940-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"},{"label":"Shares","value":"9,489.488 shares of Series J Preferred Stock"},{"label":"Purchaser","value":"David A. Jenkins and FatBoy Capital, LP"},{"label":"Consideration","value":"accrued royalty amounts totaling a net present value equal to $9,489,487.81"}],"fact_type":"equity_issuance"},{"claim_id":"061fcd77f48b1602c2657a0f2d301537a4ba00b7","claim":"Catheter Precision, Inc.: Filed Series J Certificate of Designation with Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026, to establish Series J Convertible Preferred Stock (effective 2026-02-09).","evidence_excerpt":"as further described by the Certificate of Designation of Preferences, Rights and Limitations of Series J Convertible Preferred Stock which was filed with the Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026 (the \"Series J Certificate of Designation\")","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003940/0001437749-26-003940-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-02-09"}],"fact_type":"governance_change"},{"claim_id":"6a0f30723c1caf2669901a01c6a6c62c0e62968e","claim":"Catheter Precision, Inc. entered into Series J Exchange Agreements with David A. Jenkins and FatBoy Capital, LP valued at $9,489,487.81 (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, Catheter Precision, Inc., a Delaware corporation (the \"Company\"), entered into Series J Exchange Agreements (the \"Exchange Agreements\") with David A. Jenkins and FatBoy Capital, LP. (the \"Holders\") to convert royalty rights and accrued royalty right amounts into 2,491.293 shares and 6,998.195 shares, respectively of the Company's newly created Series J Convertible Preferred Stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003940/0001437749-26-003940-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"David A. Jenkins and FatBoy Capital, LP"},{"label":"Value","value":"$9,489,487.81"},{"label":"Effective","value":"2026-02-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}